Today: 11 November 2025
Subscribe
Browse Category

Biotechnology News 15 October 2025 - 17 October 2025

Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Stock Price Surge & Recent Performance Achieve Life Sciences stock exploded higher on the FDA news, reflecting growing optimism around cytisinicline’s prospects. In pre-market trading on Oct. 17, ACHV jumped about 22.7% after the company revealed it received a rare FDA Commissioner’s National Priority Voucher (CNPV) for cytisinicline’s vaping cessation indication investing.com. This rally propelled the shares to multi-month highs in the mid-$3 range. Earlier in the week, ACHV had already begun gaining momentum – on Oct. 15 the stock broke above its 200-day moving average (~$2.81) and hit $3.19 marketbeat.com, a bullish technical signal. As of Thursday’s close (Oct.
17 October 2025
 ·  ·  ·  ·  · 
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAIL (GRAL) Rockets to Record High on Samsung Mega-Deal and Cancer Test Breakthrough

Samsung Partnership Sparks Stock Surge GRAIL, Inc. (NASDAQ: GRAL) shares soared to record highs this week after the company announced a strategic collaboration with Samsung. On October 16, GRAIL revealed a binding agreement in which Samsung C&T and Samsung Electronics will invest $110 million into GRAIL at $70.05 per share ts2.tech. In return, Samsung C&T gains exclusive rights to distribute GRAIL’s Galleri multi-cancer early detection blood test in South Korea, with plans to expand to Japan and Singapore ts2.tech. Samsung Electronics will explore technology tie-ups, integrating its digital health platforms and AI with GRAIL’s cancer-detection technology tradingview.com prnewswire.com. Investors cheered the
17 October 2025
 ·  ·  ·  ·  · 
Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

FEMY Stock Soars on Fertility Buzz Femasys stock has been on a rollercoaster ride in recent sessions. As of October 17, 2025, FEMY traded around the mid-$0.70s per share – more than double its price just a few weeks prior, and well off its 52-week low near $0.31 ts2.tech. On October 16, the stock spiked dramatically: opening near $0.55, it rallied to an intraday high of $0.84 (+52%) before settling at $0.745 (+35%) by the close finance.yahoo.com. This explosive move came amid unusually heavy volume (tens of millions of shares traded, versus ~7 million on a typical day) stockinvest.us, indicating
17 October 2025
 ·  ·  ·  ·  · 
Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

PRAX Stock Soars on Historic Trial Win Praxis Precision Medicines stock has seen a record-breaking spike in recent days after announcing landmark clinical trial results. On October 16, PRAX shares closed at $162.71, up about 183% in a single session ts2.tech ts2.tech. The stock, which had closed at $57.35 the day prior, more than tripled to reach new 52-week highs ts2.tech. Intra-day, PRAX briefly touched as high as $205 as enthusiasm peaked google.com. By midday Thursday, the company was on track to add roughly $2.7 billion to its market capitalization if gains held ts2.tech – catapulting Praxis’s valuation from around $1 billion
17 October 2025
 ·  ·  ·  ·  · 
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

Strategic Samsung Partnership GRAIL’s shares surged after it announced a deal on Oct. 16 to partner with Samsung in Asia. The binding Letter of Intent involves Samsung C&T and Samsung Electronics investing $110 million in GRAIL at $70.05 per share, with Samsung C&T to distribute the Galleri multi-cancer screening test in South Korea investing.com prnewswire.com. This collaboration gives Samsung “a strong foothold for expanding into the cancer screening field”, according to Jaywoo Kim, EVP of Samsung C&T prnewswire.com. GRAIL’s President of International Business, Sir Harpal Kumar, said the deal “strengthens our balance sheet and provides further cash runway” as the company
16 October 2025
 ·  ·  ·  ·  · 
Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Stock Rebounds on Moderna’s “Make-or-Break” Week Moderna’s stock is back in the spotlight after a turbulent week of news that sent the Nasdaq-listed shares swinging. On Wednesday, MRNA jumped over 5%, climbing to around $27.7 by market close marketbeat.com. The mini-rally came amid a flurry of developments – from upbeat trial data on a new cancer vaccine to analysts debating whether Moderna’s future is bright or bleak. Even after the pop, however, Moderna’s stock is a shadow of its former self: shares have cratered roughly 80% below last year’s levels marketbeat.com and are down one-third in 2025 alone. The once
16 October 2025
 ·  ·  ·  ·  · 
Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Market Outlook With the stock now trading well above $150, investors are debating how much further PRAX could rise. If ulixacaltamide wins approval, analysts believe it could capture a sizable ET market. However, success in neurology trials can be binary – failures or setbacks could send the stock sharply down. Looking ahead, Praxis expects more data by late 2025/early 2026 (e.g. vormatrigine POWER1 topline, PRAX-562 EMBOLD readout nasdaq.com neurologylive.com). Management’s guidance (via press releases and presentations) has focused on these milestones rather than concrete revenue forecasts, which is typical for clinical-stage biotechs nasdaq.com. In the near term, analysts will scrutinize
16 October 2025
 ·  ·  ·  ·  · 
Sana Biotechnology (SANA) Stock Skyrockets on ‘100-Bagger’ Hype – Experts Debate What’s Next

Sana Biotechnology (SANA) Stock Skyrockets on ‘100-Bagger’ Hype – Experts Debate What’s Next

Surge Fueled by a ‘100-Bagger’ Tweet Sana Biotechnology’s stock skyrocketed mid-week after a bold endorsement from a well-known tech investor. On Oct. 15, SANA shares jumped over 25% in a single session, closing at $5.62 (up from $4.45 the day prior) ts2.tech. In intraday trading the stock even hit roughly $6.55 before paring back gains ts2.tech. The catalyst? A viral post on social media. Hedge fund manager Eric Jackson — known for spotting high-growth plays — proclaimed on X (formerly Twitter) that “Biotech is back… $SANA looks like the next 100-bagger platform”. He pointed to an improving macro backdrop (lower
16 October 2025
 ·  ·  ·  ·  · 
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Biotech Bombshell: Omeros Stock Skyrockets on $2.1B Novo Nordisk Deal – What’s Next?

Stock Performance: Recent Surge and Volatility Omeros shares were trading around $4–$4.60 through early October, then exploded on Oct. 15. Data from the company’s IR site show OMER jumped from $4.10 (Oct 14 close) to $10.42 by Oct 15 close investor.omeros.com. Intraday on Oct 15, it even hit a high around $12.10. This roughly 150% one-day surge was driven by the Novo Nordisk deal (see below). Trading volume was staggering: Benzinga reports ~89.2 million shares traded (vs. a ~1.1M daily average) during the rally benzinga.com. By mid-October 16 pre-market, OMER was around $9–10 per share – still far above levels seen
16 October 2025
 ·  ·  ·  ·  ·  · 
Sana Biotech Shares Skyrocket on 100x Hype – What’s Behind the Rally?

Sana Biotech Shares Skyrocket on 100x Hype – What’s Behind the Rally?

Stock Surge Fueled by ‘100-Bagger’ Tweet On Oct. 15, SANA spiked as investors reacted to hedge fund manager Eric Jackson’s bullish call. In a post on X (formerly Twitter), Jackson proclaimed: “Biotech is back. Rates are falling, inflation is cooling, and money is rotating from megacaps to growth again,” and suggested “$SANA looks like the next 100-Bagger platform” benzinga.com. Benzinga and other outlets noted that this endorsement sent SANA shares up sharply that morning benzinga.com. (Trading was even halted several times due to the rapid move.) Earlier in the week, SANA’s stock had been quietly rallying on general biotech enthusiasm
15 October 2025
 ·  ·  ·  ·  · 
Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Volatile Stock Performance in October 2025 Recursion’s stock showed wild swings in early October. On Oct 7, 2025 the shares fell about 5.4% to ~$5.23 amid a broad market slump nasdaq.com. The very next day (Oct 8) the stock rebounded sharply, jumping roughly 16% to ~$6.08 ts2.tech. This put RXRX near the middle of its 52-week trading range (about $3.97–$10.87) ts2.tech. Trading volume on these moves was heavy, with tens of millions of shares changing hands as investors positioned for upcoming company news. By Oct 14, RXRX was around $5.89 stocktitan.net. This volatility appears driven by renewed enthusiasm for Recursion’s
15 October 2025
 ·  ·  ·  ·  · 
Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

SEED Stock Soars on Market Momentum Origin Agritech’s stock skyrocketed this week, delivering eye-popping gains for investors. On Tuesday night, SEED shares surged over 92% in after-hours trading following a flurry of positive developments benzinga.com. The price spiked from the $1.40 range to roughly $2.76 in extended trading – nearly a doubling overnight. By Wednesday Oct. 15, the stock opened sharply higher before paring back to about $1.43 by mid-day investing.com, roughly flat from Tuesday’s official close of $1.44 benzinga.com. This explosive move came amid a broader rally in agricultural and biotech shares. U.S. political news turbocharged the sector: a
15 October 2025
 ·  ·  ·  ·  · 
1 … 3 4 5 6 7 8
Go toTop